US FDA Biosimilars Staff Faces More Transition As Sue Lim Departs After Christl

Leah Christl isn't the only high-level member the US FDA's Therapeutic Biologics and Biosimilars Staff (TBBS) is losing to the private sector this month. Sue Lim, who serves as TBBS' director of the scientific review staff, will be leaving the agency at the end of February to start an independent consulting firm, the Pink Sheet has learned.

An FDA spokesperson told the Pink Sheet that Stacey Ricci, a senior staffer who has been with TBBS for four years, will take over Lim's role in an acting